Free shipping on all orders over $ 500


Cat. No. M9161
NVP-ACC789 Structure

ACC-789; ZK-202650

Size Price Availability Quantity
10mM*1mL USD 120  USD120 In stock
5mg USD 107  USD107 In stock
10mg USD 147  USD147 In stock
25mg USD 295  USD295 In stock
50mg USD 445  USD445 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

NVP-ACC789, also known as ACC-789 and ZK-202650, is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases with potential anticancer activity. NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM. 

In Vivo, NVP-ACC789 oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 405.29
Formula C21H17BrN4
CAS Number 300842-64-2
Purity >98%
Solubility DMSO: ≥ 47 mg/mL (Need ultrasonic and warming)
Storage at -20°C

[1] Tille JC, et al. J Pharmacol Exp Ther. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.

Related VEGFR/PDGFR Products

Pamufetinib (TAS-115) is a highly potent inhibitor of both C-MET and VEGFR, with IC50 of 30 nM and 32 nM against recombinant VEGFR2 and VEGFR, respectively.


Chiauranib (CS2164) is a multi-target inhibitor with oral activity against tumor angiogenesis. Chiauranib effectively inhibits angiogenesis-associated kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-associated kinase Aurora B, and chronic inflammation-associated kinase CSF-1R,IC50 The value is 1-9 nM. Chiauranib has a strong anti-cancer effect.

TAS-115 mesylate

TAS-115 (Pamufetinib) mesylate inhibited the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors.


Ningetinib is a potent, orally bioavailable tyrosine kinase inhibitor for Axl, VEGFR2 and c-Met with IC50 values of <1.0, 1.9 and 6.7 nM, respectively.

Tanshinone IIA

Tanshinone IIA suppresses angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2. *The compound is unstable in solutions, freshly prepared is recommended.

Abmole Inhibitor Catalog 2017

Keywords: NVP-ACC789, ACC-789; ZK-202650 supplier, VEGFR/PDGFR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.